Bleeding News and Research

RSS

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel Pharmaceuticals, Inc. today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura).

16 Jul 2014

Study: History of stroke associated with increased risk of adverse events after elective noncardiac surgery

In an analysis that included more than 480,000 patients who underwent elective noncardiac surgery, a history of stroke was associated with an increased risk of major adverse cardiovascular events and death, particularly if time elapsed between stroke and surgery was less than 9 months, according to a study in the July 16 issue of JAMA.

16 Jul 2014

Radial artery catheterization much safer for women

Instead of going through the groin during heart catheterizations, physicians can now insert the catheter through a patient's wrist, a less traumatic and safer option for some patients — especially women.

14 Jul 2014

Researchers invent injectable foam system to stop profuse bleeding from wound

Without prompt care, a badly wounded soldier can easily bleed to death while being transported to a distant medical station. Two traditional treatments—tourniquets and medicated gauze pads—often cannot stop the blood loss from a deep wound at the neck, shoulder or groin.

11 Jul 2014

Endomedix develops spray-on gel to staunch bleeding during brain surgery

Endomedix, a start-up company housed at NJIT's business incubator, received a $1.4 million federal grant to develop a spray-on gel that surgeons will use to staunch bleeding during brain surgery.

11 Jul 2014

Study: Minimally invasive aortic repair procedure safer for patients

Researchers at the University of California, San Diego School of Medicine have documented the safety benefits of aortic stent grafts inserted during minimally invasive surgery to repair abdominal aortic aneurysms - weaknesses in the body's largest artery that can rupture, causing potentially lethal internal bleeding.

10 Jul 2014

Pain control in osteoarthritis patients

Osteoarthritis (OA) is one of the most common causes of disability, and inadequate pain control can lead to joint stiffness that may impair mobility for patients.

9 Jul 2014

Cheaper drug could potentially improve heart attack patient outcomes and save health services millions

A new study published in The Lancet compares outcomes for two drugs used to prevent blood clot formation during emergency heart attack treatment. The study suggests that use of one of the drugs, heparin, could result in improved outcomes (such as a reduced rate of repeat heart attacks), compared to the other drug tested, bivalirudin, which is in widespread use in high-income countries, and is around 400 times more expensive than heparin.

7 Jul 2014

Treating ulcerative colitis and Crohn’s disease

Ulcerative colitis and Crohn’s disease are idiopathic (we don’t know the cause) inflammatory diseases (IBD) of the colon and/or small bowel. They are chronic in that we do not have a medical cure and are differentiated from IBS (irritable bowel syndrome) by inflammation that causes ulcerations of the GI tract.

7 Jul 2014

Headbanging to Motörhead thought to have caused bleeding in the brain

A recent report in the Lancet describes the case of a man who developed bleeding in the brain after headbanging at a Motörhead concert.

4 Jul 2014

Aspirin, smoking influence aging processes of female genome connected to colorectal cancer

The risk of developing cancer increases with age. Factors like smoking and regular aspirin use also affect the risk of cancer - although in the opposite sense. Researchers from the University of Basel were now able to show that aspirin use and smoking both influence aging processes of the female genome that are connected to colorectal cancer.

1 Jul 2014

Tonsillectomy in adults improves quality of life

Tonsillectomy for recurrent pharyngitis in adults improves quality of life for the overwhelming majority of patients, report researchers.

30 Jun 2014

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency to expand the label for VELCADE (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated Mantle Cell Lymphoma (MCL).

28 Jun 2014

New guidelines to protect burn victims from hypothermia risk during surgery

Loyola University Health System has established new guidelines to protect burn victims at risk for hypothermia during surgery.

26 Jun 2014

Researchers develop self-powered artificial cardiac pacemaker

As the number of pacemakers implanted each year reaches into the millions worldwide, improving the lifespan of pacemaker batteries has been of great concern for developers and manufacturers.

23 Jun 2014

Bayer, Dimension Therapeutics partner to develop new gene therapy for hemophilia A

Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy treatments for rare diseases, today announced it has entered into a collaboration with Bayer HealthCare (Bayer) for the development and commercialization of a novel gene therapy for the treatment of hemophilia A.

23 Jun 2014

Genetic variants linked to race that explains risk of death among patients taking Plavix after heart attack

Researchers have identified the first genetic variations linked to race that begin to explain a higher risk of death among some African American and Caucasian patients taking the anti-clotting drug clopidogrel (Plavix) after a heart attack.

18 Jun 2014

New strategy for treating neuroblastoma using modified version of heparin

Researchers at Duke Medicine have identified a new strategy for treating neuroblastoma using a modified version of heparin, a century-old injectable drug that thins the blood to prevent clots from forming.

18 Jun 2014

Clot-busting medications for treating pulmonary embolism patients linked with fewer deaths

Bringing clarity to a decades-long debate, a national team of researchers led by experts from the Perelman School of Medicine at the University of Pennsylvania has found that adding clot-busting medications known as thrombolytics to conventional approaches when treating sudden-onset pulmonary embolism patients is associated with 47 percent fewer deaths than using standard intravenous or under-the-skin anticoagulant medications alone.

18 Jun 2014

New computer models predict outcome of treatments for TBI

Most people who suffer a severe brain injury take years to recover - if they recover at all. But the right treatment in the crucial hours following an accident can make all the difference.

16 Jun 2014